Source:http://linkedlifedata.com/resource/pubmed/id/10617843
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0025202,
umls-concept:C0030705,
umls-concept:C0034897,
umls-concept:C0042160,
umls-concept:C0205095,
umls-concept:C0205173,
umls-concept:C0205210,
umls-concept:C0205549,
umls-concept:C0220901,
umls-concept:C0302350,
umls-concept:C0439806,
umls-concept:C0868928,
umls-concept:C1522449,
umls-concept:C1547011,
umls-concept:C1879746
|
pubmed:issue |
10
|
pubmed:dateCreated |
2000-1-28
|
pubmed:abstractText |
We describe two comparative series of patients treated with double-dose betaraysbrachytherapy (106 Ruthenium) between 1983 and 1994, and double-dose proton beam therapy between 1991 and 1996. The indications for double-dose irradiation with the same radio-element corresponded to "macroscopically abnormal" situations: immediate and prolonged radioresistance, recurrence or secondary radioresistance. Thirteen cases are called series 1 (Ruthenium) and 6 cases are called series 2 (protons). The series 1 allows a more reliable study as far as follow-up is higher (5.8 to 7.5 years) than in series 2 where the follow-up is shorter (13.6 to 29 months). Although double-dose irradiation was macroscopically efficient in 11 out of 13 cases in series 1, and in 3 out of 6 cases in series 2 (stabilization or decrease of tumour height measured before the second therapeutic session), 2 patients are deceased and 1 has a metastatic disease in the group "recurrence" of Ruthenium serie. Another one has also a metastatic disease in the group "recurrence" of protons series. Nevertheless double-dose radiotherapy allows a complementary decrease or stabilization of tumour height after a first session. It also decreases the indications for enucleation if there is no severe anatomic complications, when a tumour does not regress or recurs after a first session of radiations.
|
pubmed:language |
fre
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0181-5512
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1054-63
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10617843-Adult,
pubmed-meshheading:10617843-Aged,
pubmed-meshheading:10617843-Aged, 80 and over,
pubmed-meshheading:10617843-Brachytherapy,
pubmed-meshheading:10617843-Female,
pubmed-meshheading:10617843-Follow-Up Studies,
pubmed-meshheading:10617843-Humans,
pubmed-meshheading:10617843-Male,
pubmed-meshheading:10617843-Melanoma,
pubmed-meshheading:10617843-Middle Aged,
pubmed-meshheading:10617843-Neoplasm Metastasis,
pubmed-meshheading:10617843-Neoplasm Recurrence, Local,
pubmed-meshheading:10617843-Prognosis,
pubmed-meshheading:10617843-Radiation Tolerance,
pubmed-meshheading:10617843-Reproducibility of Results,
pubmed-meshheading:10617843-Retrospective Studies,
pubmed-meshheading:10617843-Time Factors,
pubmed-meshheading:10617843-Uveal Neoplasms
|
pubmed:year |
1999
|
pubmed:articleTitle |
[Double irradiation for macroscopic radioresistance or recurrence of melanomas of the posterior uvea: clinical, ballistic, therapeutic and prognostic aspects. Series of 19 cases among 462 patients].
|
pubmed:affiliation |
Clinique Ophtalmologique Universitaire, Hôpital de la Croix-Rousse, 93, grande rue, 69004 Lyon.
|
pubmed:publicationType |
Journal Article,
English Abstract
|